172 related articles for article (PubMed ID: 37247278)
1. High Indoleamine 2,3-Dioxygenase Expression along with Low Bridging Integrator-1 Expression in Hepatocellular Carcinoma Patients.
Asghar K; Rana IA; Abubakar M; Hasham K; Tahseen M; Bilal S; Mehmood S; Farooq A; Siddique K; Loya A
Asian Pac J Cancer Prev; 2023 May; 24(5):1591-1600. PubMed ID: 37247278
[TBL] [Abstract][Full Text] [Related]
2. Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients.
Jia Y; Wang H; Wang Y; Wang T; Wang M; Ma M; Duan Y; Meng X; Liu L
Int J Cancer; 2015 Sep; 137(5):1095-106. PubMed ID: 25683635
[TBL] [Abstract][Full Text] [Related]
3. Characterization of bridging integrator 1 (BIN1) as a potential tumor suppressor and prognostic marker in hepatocellular carcinoma.
Pan K; Liang XT; Zhang HK; Zhao JJ; Wang DD; Li JJ; Lian Q; Chang AE; Li Q; Xia JC
Mol Med; 2012 May; 18(1):507-18. PubMed ID: 22281836
[TBL] [Abstract][Full Text] [Related]
4. Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma.
Asghar K; Farooq A; Zulfiqar B; Rashid MU
World J Gastroenterol; 2017 Apr; 23(13):2286-2293. PubMed ID: 28428708
[TBL] [Abstract][Full Text] [Related]
5. Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma.
Pan K; Wang H; Chen MS; Zhang HK; Weng DS; Zhou J; Huang W; Li JJ; Song HF; Xia JC
J Cancer Res Clin Oncol; 2008 Nov; 134(11):1247-53. PubMed ID: 18438685
[TBL] [Abstract][Full Text] [Related]
6. The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer.
Gao YF; Peng RQ; Li J; Ding Y; Zhang X; Wu XJ; Pan ZZ; Wan DS; Zeng YX; Zhang XS
J Transl Med; 2009 Aug; 7():71. PubMed ID: 19695096
[TBL] [Abstract][Full Text] [Related]
7. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.
Han Y; Chen Z; Yang Y; Jiang Z; Gu Y; Liu Y; Lin C; Pan Z; Yu Y; Jiang M; Zhou W; Cao X
Hepatology; 2014 Feb; 59(2):567-79. PubMed ID: 23960017
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.
Muller AJ; DuHadaway JB; Donover PS; Sutanto-Ward E; Prendergast GC
Nat Med; 2005 Mar; 11(3):312-9. PubMed ID: 15711557
[TBL] [Abstract][Full Text] [Related]
9. [Relationship between the expressions of indoleamine 2, 3-dioxygenase in hepatocellular carcinoma and clinicopathological parameters].
Lin L; Yang DH; Huang Y; Li XH; Zhang QL; Liu X; Liang JK; Zhong KB; He H
Zhonghua Yi Xue Za Zhi; 2013 Jul; 93(28):2186-90. PubMed ID: 24169325
[TBL] [Abstract][Full Text] [Related]
10. Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma.
Ishio T; Goto S; Tahara K; Tone S; Kawano K; Kitano S
J Gastroenterol Hepatol; 2004 Mar; 19(3):319-26. PubMed ID: 14748880
[TBL] [Abstract][Full Text] [Related]
11. High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes.
Ahmadzada T; Lee K; Clarke C; Cooper WA; Linton A; McCaughan B; Asher R; Clarke S; Reid G; Kao S
Lung Cancer; 2019 Apr; 130():35-41. PubMed ID: 30885349
[TBL] [Abstract][Full Text] [Related]
12. Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.
Brown ZJ; Yu SJ; Heinrich B; Ma C; Fu Q; Sandhu M; Agdashian D; Zhang Q; Korangy F; Greten TF
Cancer Immunol Immunother; 2018 Aug; 67(8):1305-1315. PubMed ID: 29959458
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 is Fascinating but IDO Needs Attention in Non-HCV and Non-HBV-Associated Hepatocellular Carcinoma Patients.
Asghar K; Bashir S; Ali Rana I; Abu Bakar M; Farooq A; Hassan M; Asif Z; Afzal M; Masood I; Ishaq M; Tahseen M; Bilal S; Mehmood S; Kanwal N; Ud Din I; Loya A
J Hepatocell Carcinoma; 2023; 10():921-934. PubMed ID: 37350801
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.
Brandacher G; Perathoner A; Ladurner R; Schneeberger S; Obrist P; Winkler C; Werner ER; Werner-Felmayer G; Weiss HG; Göbel G; Margreiter R; Königsrainer A; Fuchs D; Amberger A
Clin Cancer Res; 2006 Feb; 12(4):1144-51. PubMed ID: 16489067
[TBL] [Abstract][Full Text] [Related]
15. The Role of Indoleamine 2,3-Dioxygenase in Diethylnitrosamine-Induced Liver Carcinogenesis.
Shibata Y; Hara T; Nagano J; Nakamura N; Ohno T; Ninomiya S; Ito H; Tanaka T; Saito K; Seishima M; Shimizu M; Moriwaki H; Tsurumi H
PLoS One; 2016; 11(1):e0146279. PubMed ID: 26727596
[TBL] [Abstract][Full Text] [Related]
16. Mechanism and prognostic value of indoleamine 2,3-dioxygenase 1 expressed in hepatocellular carcinoma.
Li S; Han X; Lyu N; Xie Q; Deng H; Mu L; Pan T; Huang X; Wang X; Shi Y; Zhao M
Cancer Sci; 2018 Dec; 109(12):3726-3736. PubMed ID: 30264546
[TBL] [Abstract][Full Text] [Related]
17. H
Yang D; Li T; Li Y; Zhang S; Li W; Liang H; Xing Z; Du L; He J; Kuang C; Yang Q
J Exp Clin Cancer Res; 2019 Feb; 38(1):88. PubMed ID: 30777103
[TBL] [Abstract][Full Text] [Related]
18. Association between Cyclooxygenase-2 and Indoleamine 2,3-Dioxygenase Expression in Breast Cancer Patients from Pakistan.
Asghar K; Loya A; Rana IA; Abu Bakar M; Farooq A; Tahseen M; Ishaq M; Rashid MU
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3521-3525. PubMed ID: 31759380
[TBL] [Abstract][Full Text] [Related]
19. IDO and intra-tumoral neutrophils were independent prognostic factors for overall survival for hepatocellular carcinoma.
Wang Y; Yao R; Zhang L; Xie X; Chen R; Ren Z
J Clin Lab Anal; 2019 Jun; 33(5):e22872. PubMed ID: 30843276
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of indoleamine 2,3-dioxygenase activity and expression in nasopharyngeal carcinoma.
Ben-Haj-Ayed A; Moussa A; Ghedira R; Gabbouj S; Miled S; Bouzid N; Tebra-Mrad S; Bouaouina N; Chouchane L; Zakhama A; Hassen E
Immunol Lett; 2016 Jan; 169():23-32. PubMed ID: 26608400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
